Pitolisant for Prader-Willi syndrome in ongoing study
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study tests an oral medication, pitolisant, in people with Prader-Willi syndrome who have already been in a pitolisant study. It aims to see if continuing treatment is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You took part in a previous study of the drug pitolisant and finished it.
- You are willing to use birth control during and for a short time after the study (if you could become pregnant or get someone pregnant).
- You are not breastfeeding or planning to breastfeed during the study.
- Your kidneys are working well enough (no dialysis needed).
- You do not have a high risk of suicide based on recent screenings or doctor's judgment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called pitolisant to see if it helps reduce excessive daytime sleepiness in people with Prader-Willi syndrome. You or your loved one may be able to join if they have a confirmed diagnosis and a caregiver who can regularly help with study tasks.
This trial tests an investigational drug called CSTI-500 for people with Prader-Willi syndrome who are in the hyperphagia (constant hunger) phase. It aims to see if the drug can improve behavior and reduce overeating. You and your caregiver will need to visit the clinic regularly and answer questions about symptoms.
This trial tests an experimental drug called BMB-101 to see if it can help control extreme hunger in adults with Prader-Willi Syndrome. It aims to improve safety and quality of life.
This trial studies whether taking prebiotics and probiotics can help children with Prader-Willi syndrome manage obesity. It’s testing a gut-focused approach to weight control over the study period.
This study tests the diabetes/weight-loss drug tirzepatide (Mounjaro) in young adults aged 18–26 who have obesity and either Prader-Willi syndrome, hypothalamic obesity, or general obesity. It looks at whether a weekly injection can help with weight management.
This study tests whether growth hormone treatment is safe and helpful for adults who have Prader-Willi syndrome. You might be considered if your diagnosis is confirmed and certain health risks—like diabetes and sleep breathing problems—are under control.
Hear when a new Prader-Willi Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.